A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of Fedratinib compared to best available therapy in subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and previously treated with ruxolitinib (The FREEDOM 2 trial)

  • Perkins, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

Effective start/end date16/12/1931/12/25


  • Malignant Haematology
  • Myelofibrosis
  • Clinical trial